Insider buying last 90 days
No open-market insider purchases were filed for CVS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CVS insider filing, plotted on the chart in Gekko.Open CVS in Gekko
NYSE: CVS
CVS Health (CVS) Stock Analysis & Forecast
$88.84−1.43 (−1.6%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryCVS Health closes at $88.84, down 1.6%, sitting between its 50-day average of $98.95 and 200-day average of $87.24. The GekkoIndex reads 75.1, placing the stock in the Buying zone. Gap to Gekko Fair Value of $164.82 stands at -46.1%, with the stock down 5.1% over one month but up 23.6% over six months and 20.1% over the past year.
This week's coverage centers on Aetna's expansion of prior authorization bundles for oncology treatment, covering all cancer types for eligible Medicaid members, with full rollout across all Aetna businesses planned for 2027, aimed at simplifying provider approvals. Separately, CVS Pharmacy agreed to a $20.5 million settlement in a digital privacy class action, with eligible consumers able to claim up to $10. Institutional activity was also noted, with Nykredit A/S acquiring 2.03 million shares valued at approximately $209.8 million, and coverage pointed to CVS trading well below Wall Street targets following the month's pullback.
Earnings are scheduled for 4 November 2026, 45 days out, before the open, following a Q2 report where adjusted EPS of $2.58 beat the $1.87 estimate and full-year guidance was raised to $7.90–$8.10, though shares reacted -7.9% afterward. Analyst coverage shows 17 buy ratings against 1 hold among 18 firms, with a consensus target of $116.28. Seasonality over the next 20 trading days has averaged +2.1% across 5 years, rising in 3 of them, worth noting alongside the current gap to fair value.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $88.84200-day averageGekko Fair Value $164.82
Key stats
- Market cap
- $113.4B
- P/E ratio
- 24.2
- Forward P/E
- 10.9
- EPS, TTM
- $3.73
- Revenue, TTM
- $412.6B
- Profit margin
- 1.2%
- Dividend yield
- 2.90%
- Beta
- 0.58
- Volume
- 21.66M avg 6.49M
- 1-year return
- +20.1%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5.3%
- 50-day average
- $98.95
- 200-day average
- $87.24
- Next earnings
- Nov 4 before open
- Shares outstanding
- 1.28B
CVS Health swing-trade checklist
CVS Health scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $88.84 sits between the 50-day ($98.95) and 200-day ($87.24) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
75.1, Buying
Reading 75.1 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
46.1% below
Price is 46.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 45 days
Next report Nov 4, 2026, 45 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.1% on average
From this point in the calendar, the next 20 trading days averaged +2.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
CVS Health stock chart and price history
CVS Health closed at $88.84 on Sep 18, 2026, +20.1% over the past year, inside a 52-week range of $69.51 to $110.68.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.1%
- 3 months
- −9.6%
- 6 months
- +23.6%
- 1 year
- +20.1%
The full CVS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CVS in Gekko
Follow CVS Health through every session
Put CVS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CVS in GekkoFree for 7 days. No credit card required.
About CVS Health
CVS Health operates in the healthcare space, bringing together insurance, pharmacy management, and drugstore services for consumers and patients. It has become known for offering a wide net of care options, from medical coverage to filling prescriptions and treating people in clinics, online, and in their homes.
The business runs across four segments. One focuses on health insurance coverage, another manages pharmacy benefits and delivers clinical care through virtual visits, home services, and medical clinics. A separate segment handles prescription dispensing at retail pharmacy locations and through infusion services, while the remaining segment covers corporate management and administrative functions.
Stanley P. Goldstein and Ralph Hoagland started the business back in 1963, and it now runs its operations out of Woonsocket, Rhode Island. Shares of CVS Health trade on the NYSE under the ticker CVS.
- Listed
- NYSE
- Sector
- Retail trade
- Industry
- Drugstore chains
- Website
- cvshealth.com
CVS Health GekkoIndex: the smart money zone
CVS Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 75.1, in the Buying zone, up 13 points over five sessions.
75.1Buying
Up 13 points over five sessions, from the Accumulation zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 34 | +1.0% | +10.6% | ||
| Accumulation | 191 | +0.6% | +2.3% | ||
| Neutral | 406 | +0.3% | +0.4% | ||
| Distribution | 30 | −1.1% | −2.8% | ||
| Selling | 1 | Too few readings yet | |||
Average CVS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the CVS price, zone by zone.Track CVS in Gekko
Is CVS Health stock overvalued? Gekko Fair Value
CVS Health trades 46.1% below Gekko Fair Value of $164.82, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what CVS Health shares are worth, recalculated every trading day.
$164.82
Gekko Fair Value, Sep 19, 2026
46.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CVS in Gekko
CVS Health insider and Congress trading
No open-market insider purchases were filed for CVS Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CVS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CVS, plotted on the chart in Gekko.Open CVS in Gekko
Buybacks
CVS Health has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2024
- $1.00M
- As a share of market cap
- 0.00%
- Trailing four quarters
- $3.03B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
4of the funds Gekko tracks hold CVS.
0added2opened2trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
CVS Health earnings: next date and track record
CVS Health reports on Nov 4, 2026, before the open (45 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 45 days away
- EPS estimate
- $1.60
- Revenue estimate
- $104.5B
7 of 8reports beat the EPS estimate
±6.2%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- CVS Health reported strong Q2 2026 results with broad-based revenue and earnings growth across all operating segments. Adjusted operating income was $5.2 billion and adjusted EPS was $2.58, driving management to raise full-year 2026 adjusted EPS guidance by $0.60 to $7.90–$8.10 and to increase expected cash flow from operations to at least $11.5 billion. Management highlighted execution on strategic priorities including technology and AI investments, growth in specialty pharmacy, momentum in the retail pharmacy (PCW) business, and multi-channel initiatives to serve demand for GLP-1 therapies (both funded and direct-to-consumer). They reiterated long-term EPS growth targets (mid-teens CAGR / Investor Day targets) and provided an early floor for 2027 adjusted EPS at ~$8.44 while noting key dynamics being monitored for 2027. During Q&A, management discussed headwinds including 340B pressures, a more normalized selling/renewal environment, potential membership dynamics, and challenges from the No Surprises Act/IDR process, while emphasizing multiple paths to outperformance and continued investments in AI and consumer-facing technology.
- Guidance
- Raised 2026 adjusted EPS guidance to $7.90–$8.10 (up $0.60). Updated 2026 cash flow from operations expectation to at least $11.5 billion (up $2.0 billion). Early high-level commentary for 2027: provided a possible floor of $8.44 adjusted EPS for 2027 (consistent with consensus) and reiterated long-term mid-teens EPS CAGR target (Investor Day targets remain intact). Assumes only offsetting dilution (no share repurchase assumed) in 2027 at this time.
- Risks flagged
- 340B program pressures and manufacturer restrictions impacting covered entities; a less active selling season/renewals affecting retention and membership; potential membership impacts from exit of individual exchange business; No Surprises Act / independent dispute resolution (IDR) process being abused by some providers creating cost trend pressure; affordability and access issues around GLP-1 therapies; general regulatory and macro uncertainty.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $2.58 est $1.87 | $106.1B est $100.0B | −7.9% |
| May 6, 2026 | $2.57 est $2.18 | $100.4B est $94.99B | +8.3% |
| Feb 10, 2026 | $1.09 est $1.00 | $105.7B est $103.7B | +1.6% |
| Oct 29, 2025 | $1.60 est $1.37 | $102.9B est $98.81B | −6.7% |
| Jul 31, 2025 | $1.81 est $1.46 | $98.92B est $94.53B | +0.3% |
| May 1, 2025 | $2.25 est $1.70 | $94.59B est $93.68B | +1.1% |
| Feb 12, 2025 | $1.19 est $0.91 | $97.71B est $97.09B | +20.7% |
| Nov 6, 2024 | $1.09 est $1.44 | $95.43B est $92.75B | +3.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
CVS Health stock forecast and analyst price targets
Analysts’ average 12-month price target for CVS Health is $116.28, +30.9% from the last close, from 18 firms rating the stock in the last 90 days.
$116.28consensus 12-month target, +30.9% from the last close
Now $88.84Avg $116.28
Low $103High $125
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 15 | Wells Fargo | $123 | +38.5% |
| Sep 15 | Bank of America Securities | $120 | +35.1% |
| Sep 9 | Bernstein | $106 | +19.3% |
| Sep 9 | Wells Fargo | $123 | +38.5% |
| Sep 4 | Bernstein | $106 | +19.3% |
+10.6%average 20-day move after past Buying readings
+2.1%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
CVS Health seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, CVS Health averaged +2.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.5% | 3 of 5 |
| Next 10 trading days | +0.2% | 2 of 5 |
| Next 15 trading days | +0.5% | 2 of 5 |
| Next 20 trading days | +2.1% | 3 of 5 |
| Next 30 trading days | −0.7% | 2 of 5 |
For scale, CVS’s typical 20-trading-day move in either direction is about 5.3%.
CVS Health market cap and key statistics
CVS Health’s market cap is $113.4B, with a P/E ratio of 24.2 and revenue of $412.6B over the last twelve months.
Valuation
- Market cap
- $113.4B
- P/E ratio
- 24.2
- Forward P/E
- 10.9
- EPS, TTM
- $3.73
- Gekko Fair Value
- $164.82
Trading
- Volume
- 21.66M
- Avg volume, 20 days
- 6.49M
- 52-week high
- $110.68
- 52-week low
- $69.51
- Shares outstanding
- 1.28B
Financials
- Revenue, TTM
- $412.6B
- Profit margin
- 1.2%
- Return on equity
- 6.2%
- Quarterly earnings growth, YoY
- +188.8%
Risk and income
- Beta
- 0.58
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±5.3%
- Dividend yield
- 2.90%
CVS Health stock news this week
Coverage of CVS Health this week reads positive: 16 positive, 2 neutral and 2 negative headlines.
- CVS Health is making a difference in local communities, one classroom at a timeCVS Health, Sep 18
- Health Insurance Providers Stocks Q2 Earnings Review: CVS Health (NYSE:CVS) ShinesYahoo Finance, Sep 18
- 2,028,154 Shares in CVS Health Corporation $CVS Acquired by Nykredit A SMarketBeat, Sep 18
- Aetna expands oncology prior authorization bundlesCVS Health, Sep 17
- CVS Health's Aetna to streamline cancer treatment approvalsReuters, Sep 17
- Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to carePRNewsWire, Sep 17
CVS Health peers
CVS Health’s 1 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| GRDNGuardian Pharmacy Services | Neutral | 22.9% above |
A peer links to its own page where one exists.
CVS Health stock FAQ
What is CVS Health’s market cap?
CVS Health’s market cap is $113.4B at the Sep 18, 2026 close of $88.84, with 1.28B shares outstanding. The shares trade on a P/E ratio of 24.2.
What is the CVS Health stock forecast?
The consensus analyst 12-month price target for CVS Health is $116.28, +30.9% from the last close. Of the 18 firms that rated the stock in the last 90 days, 17 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is CVS Health stock overvalued or undervalued?
On Gekko’s estimate CVS Health is undervalued: the Sep 18, 2026 close of $88.84 is 46.1% below Gekko Fair Value of $164.82. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does CVS Health report earnings next?
CVS Health is expected to report on Nov 4, 2026, before the market opens (45 days away). Analysts expect earnings of $1.60 per share on revenue of $104.5B. CVS Health beat the earnings estimate in 7 of its last 8 reports, moving 6.2% on average across the report.
What is CVS Health’s 52-week high and low?
CVS Health’s 52-week high is $110.68 and its 52-week low is $69.51; it closed at $88.84 on Sep 18, 2026, +20.1% over the past year.
Is CVS Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See CVS Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.